{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T08:58:58Z","timestamp":1753520338559},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,10,3]],"date-time":"2015-10-03T00:00:00Z","timestamp":1443830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,10,3]],"date-time":"2015-10-03T00:00:00Z","timestamp":1443830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Microbiol Biotechnol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00253-015-7027-x","type":"journal-article","created":{"date-parts":[[2015,10,3]],"date-time":"2015-10-03T05:42:58Z","timestamp":1443850978000},"page":"1221-1230","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus"],"prefix":"10.1007","volume":"100","author":[{"given":"Man","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li\u2019ao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yefu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,3]]},"reference":[{"issue":"4","key":"7027_CR1","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1084\/jem.20051287","volume":"203","author":"D Adhikary","year":"2006","unstructured":"Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J (2006) Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 203(4):995\u20131006","journal-title":"J Exp Med"},{"issue":"12","key":"7027_CR2","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.1007\/s00253-014-5732-5","volume":"98","author":"M Ahmad","year":"2014","unstructured":"Ahmad M, Hirz M, Pichler H, Schwab H (2014) Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. Appl Microbiol Biotechnol 98(12):5301\u20135317","journal-title":"Appl Microbiol Biotechnol"},{"issue":"2","key":"7027_CR3","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.3390\/ijms14023556","volume":"14","author":"N An","year":"2013","unstructured":"An N, Ou J, Jiang D, Zhang L, Liu J, Fu K, Dai Y, Yang D (2013) Expression of a functional recombinant human basic fibroblast growth factor from transgenic rice seeds. Int J Mol Sci 14(2):3556\u20133567","journal-title":"Int J Mol Sci"},{"key":"7027_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2014.02.005","volume":"6","author":"HH Balfour Jr","year":"2014","unstructured":"Balfour HH Jr (2014) Progress, prospects, and problems in Epstein-Barr virus vaccine development. Curr Opin Virol 6:1\u20135","journal-title":"Curr Opin Virol"},{"issue":"5","key":"7027_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1634\/theoncologist.2008-0036","volume":"13","author":"A Carbone","year":"2008","unstructured":"Carbone A, Gloghini A, Dotti G (2008) EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 13(5):577\u2013585","journal-title":"Oncologist"},{"issue":"1","key":"7027_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pep.2013.08.014","volume":"92","author":"SA Cardoso","year":"2013","unstructured":"Cardoso SA, Paixao VF, Oliveira MD, Honda ER, Oliveira LL, da Silva CC, De Paula SO (2013) Dengue-1 envelope protein domain III produced in Pichia pastoris: potential use for serological diagnosis. Protein Expr Purif 92(1):9\u201313","journal-title":"Protein Expr Purif"},{"issue":"1","key":"7027_CR7","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1038\/cti.2014.27","volume":"4","author":"JI Cohen","year":"2015","unstructured":"Cohen JI (2015) Epstein-Barr virus vaccines. Clin Transl Immunol 4(1):e32","journal-title":"Clin Transl Immunol"},{"issue":"107","key":"7027_CR8","doi-asserted-by":"publisher","first-page":"107fs7","DOI":"10.1126\/scitranslmed.3002878","volume":"3","author":"JI Cohen","year":"2011","unstructured":"Cohen JI, Fauci AS, Varmus H, Nabel GJ (2011) Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med 3(107):107fs7","journal-title":"Sci Transl Med"},{"issue":"Suppl 2","key":"7027_CR9","doi-asserted-by":"publisher","first-page":"B194","DOI":"10.1016\/j.vaccine.2012.09.041","volume":"31","author":"JI Cohen","year":"2013","unstructured":"Cohen JI, Mocarski ES, Raab-Traub N, Corey L, Nabel GJ (2013) The need and challenges for development of an Epstein-Barr virus vaccine. Vaccine 31(Suppl 2):B194\u2013B196","journal-title":"Vaccine"},{"issue":"Pt 3","key":"7027_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1099\/0022-1317-70-3-729","volume":"70","author":"M Conway","year":"1989","unstructured":"Conway M, Morgan A, Mackett M (1989) Expression of Epstein-Barr virus membrane antigen gp340\/220 in mouse fibroblasts using a bovine papillomavirus vector. J Gen Virol 70(Pt 3):729\u2013734","journal-title":"J Gen Virol"},{"key":"7027_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0076-6879(09)63013-5","volume":"463","author":"JM Cregg","year":"2009","unstructured":"Cregg JM, Tolstorukov I, Kusari A, Sunga J, Madden K, Chappell T (2009) Expression in the yeast Pichia pastoris. Methods Enzymol 463:169\u2013189","journal-title":"Methods Enzymol"},{"issue":"30","key":"7027_CR12","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1016\/j.vaccine.2013.04.071","volume":"31","author":"X Cui","year":"2013","unstructured":"Cui X, Cao Z, Sen G, Chattopadhyay G, Fuller DH, Fuller JT, Snapper DM, Snow AL, Mond JJ, Snapper CM (2013) A novel tetrameric gp3501-470 as a potential Epstein-Barr virus vaccine. Vaccine 31(30):3039\u20133045","journal-title":"Vaccine"},{"issue":"1","key":"7027_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00253-011-3654-z","volume":"93","author":"LM Damasceno","year":"2012","unstructured":"Damasceno LM, Huang CJ, Batt CA (2012) Protein secretion in Pichia pastoris and advances in protein production. Appl Microbiol Biotechnol 93(1):31\u201339","journal-title":"Appl Microbiol Biotechnol"},{"issue":"9","key":"7027_CR14","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/cid\/cis613","volume":"55","author":"JF Deeken","year":"2012","unstructured":"Deeken JF, Tjen ALA, Rudek MA, Okuliar C, Young M, Little RF, Dezube BJ (2012) The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 55(9):1228\u20131235","journal-title":"Clin Infect Dis"},{"issue":"3","key":"7027_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.biotechadv.2009.01.008","volume":"27","author":"AL Demain","year":"2009","unstructured":"Demain AL, Vaishnav P (2009) Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv 27(3):297\u2013306","journal-title":"Biotechnol Adv"},{"issue":"Pt 2","key":"7027_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1099\/0022-1317-73-2-449","volume":"73","author":"S Finerty","year":"1992","unstructured":"Finerty S, Tarlton J, Mackett M, Conway M, Arrand JR, Watkins PE, Morgan AJ (1992) Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector. J Gen Virol 73(Pt 2):449\u2013453","journal-title":"J Gen Virol"},{"issue":"13","key":"7027_CR17","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/0264-410X(94)90240-2","volume":"12","author":"S Finerty","year":"1994","unstructured":"Finerty S, Mackett M, Arrand JR, Watkins PE, Tarlton J, Morgan AJ (1994) Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum. Vaccine 12(13):1180\u20131184","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"7027_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ajt.12004","volume":"13","author":"M Green","year":"2013","unstructured":"Green M, Michaels MG (2013) Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant 13(Suppl 3):41\u201354, quiz 54","journal-title":"Am J Transplant"},{"key":"7027_CR19","first-page":"171","volume":"84","author":"SY Gu","year":"1995","unstructured":"Gu SY, Huang TM, Ruan L, Miao YH, Lu H, Chu CM, Motz M, Wolf H (1995) First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 84:171\u2013177","journal-title":"Dev Biol Stand"},{"issue":"4","key":"7027_CR20","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1182\/blood-2008-03-148072","volume":"112","author":"C Gurer","year":"2008","unstructured":"Gurer C, Strowig T, Brilot F, Pack M, Trumpfheller C, Arrey F, Park CG, Steinman RM, Munz C (2008) Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 112(4):1231\u20131239","journal-title":"Blood"},{"issue":"2","key":"7027_CR21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.pep.2006.05.002","volume":"49","author":"X Han","year":"2006","unstructured":"Han X, Ye LB, Li BZ, Bo G, Cai WJ, Hong Z, She YL, Li Y, Kong LB, Wu ZH (2006) Expression, purification and characterization of the hepatitis B virus entire envelope large protein in Pichia pastoris. Protein Expr Purif 49(2):168\u2013175","journal-title":"Protein Expr Purif"},{"issue":"2\u20133","key":"7027_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0168-1656(99)00201-1","volume":"77","author":"E Hardy","year":"2000","unstructured":"Hardy E, Martinez E, Diago D, Diaz R, Gonzalez D, Herrera L (2000) Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris. J Biotechnol 77(2\u20133):157\u2013167","journal-title":"J Biotechnol"},{"issue":"10","key":"7027_CR23","doi-asserted-by":"publisher","first-page":"e1003685","DOI":"10.1371\/journal.ppat.1003685","volume":"9","author":"JB Hawkins","year":"2013","unstructured":"Hawkins JB, Delgado-Eckert E, Thorley-Lawson DA, Shapiro M (2013) The cycle of EBV infection explains persistence, the sizes of the infected cell populations and which come under CTL regulation. PLoS Pathog 9(10):e1003685","journal-title":"PLoS Pathog"},{"issue":"7\u20138","key":"7027_CR24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0264-410X(98)00248-5","volume":"17","author":"WT Jackman","year":"1999","unstructured":"Jackman WT, Mann KA, Hoffmann HJ, Spaete RR (1999) Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine 17(7\u20138):660\u2013668","journal-title":"Vaccine"},{"issue":"1","key":"7027_CR25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1016-8478(23)17060-9","volume":"12","author":"S Jung","year":"2001","unstructured":"Jung S, Chung YK, Chang SH, Kim J, Kim HR, Jang HS, Lee JC, Chung GH, Jang YS (2001) DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen. Mol Cells 12(1):41\u201349","journal-title":"Mol Cells"},{"key":"7027_CR26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4172\/2157-7560.1000150","volume":"3","author":"K Kato","year":"2012","unstructured":"Kato K, Sano H, Nagata K, Sugihara H, Kanai K, Kuwamoto S, Kato M, Murakami I, Hayashi K (2012) Synthetic peptides of Epstein-Barr virus-major envelope glycoprotein-350\/220 do not prevent infection in a rabbit Epstein-Barr virus infection model. J Vaccines Vaccin 3:148","journal-title":"J Vaccines Vaccin"},{"issue":"6","key":"7027_CR27","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1128\/AEM.02612-05","volume":"72","author":"T Kim","year":"2006","unstructured":"Kim T, Mullaney EJ, Porres JM, Roneker KR, Crowe S, Rice S, Ko T, Ullah AH, Daly CB, Welch R, Lei XG (2006) Shifting the pH profile of Aspergillus niger PhyA phytase to match the stomach pH enhances its effectiveness as an animal feed additive. Appl Environ Microbiol 72(6):4397\u20134403","journal-title":"Appl Environ Microbiol"},{"key":"7027_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.biortech.2013.02.015","volume":"134","author":"L Lu","year":"2013","unstructured":"Lu L, Wang TN, Xu TF, Wang JY, Wang CL, Zhao M (2013) Cloning and expression of thermo-alkali-stable laccase of Bacillus licheniformis in Pichia pastoris and its characterization. Bioresour Technol 134:81\u201386","journal-title":"Bioresour Technol"},{"issue":"5","key":"7027_CR29","doi-asserted-by":"publisher","first-page":"e64595","DOI":"10.1371\/journal.pone.0064595","volume":"8","author":"S Mani","year":"2013","unstructured":"Mani S, Tripathi L, Raut R, Tyagi P, Arora U, Barman T, Sood R, Galav A, Wahala W, Silva AD, Swaminathan S, Khanna N (2013) Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies. PLoS ONE 8(5):e64595","journal-title":"PLoS ONE"},{"key":"7027_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2174\/1874357901206010012","volume":"6","author":"H Mok","year":"2012","unstructured":"Mok H, Cheng X, Xu Q, Zengel JR, Parhy B, Zhao J, Wang CK, Jin H (2012) Evaluation of measles vaccine virus as a vector to deliver respiratory syncytial virus fusion protein or Epstein-Barr virus glycoprotein gp350. Open Virol J 6:12\u201322","journal-title":"Open Virol J"},{"issue":"24","key":"7027_CR31","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","volume":"25","author":"M Moutschen","year":"2007","unstructured":"Moutschen M, Leonard P, Sokal EM, Smets F, Haumont M, Mazzu P, Bollen A, Denamur F, Peeters P, Dubin G, Denis M (2007) Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 25(24):4697\u20134705","journal-title":"Vaccine"},{"issue":"3","key":"7027_CR32","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1128\/jvi.64.3.1348-1352.1990","volume":"64","author":"GR Nemerow","year":"1990","unstructured":"Nemerow GR, Mullen JJ 3rd, Dickson PW, Cooper NR (1990) Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection. J Virol 64(3):1348\u20131352","journal-title":"J Virol"},{"issue":"1","key":"7027_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/0042-6822(92)90207-6","volume":"191","author":"CM Nuebling","year":"1992","unstructured":"Nuebling CM, Buck M, Boos H, von Deimling A, Mueller-Lantzsch N (1992) Expression of Epstein-Barr virus membrane antigen gp350\/220 in E. coli and in insect cells. Virology 191(1):443\u2013447","journal-title":"Virology"},{"key":"7027_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12967-015-0415-2","volume":"13","author":"JG Ogembo","year":"2015","unstructured":"Ogembo JG, Muraswki MR, McGinnes LW, Parcharidou A, Sutiwisesak R, Tison T, Avendano J, Agnani D, Finberg RW, Morrison TG, Fingeroth JD (2015) A chimeric EBV gp350\/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice. J Transl Med 13:50","journal-title":"J Transl Med"},{"issue":"Pt 3","key":"7027_CR35","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1099\/0022-1317-74-3-501","volume":"74","author":"T Ragot","year":"1993","unstructured":"Ragot T, Finerty S, Watkins PE, Perricaudet M, Morgan AJ (1993) Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340\/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. J Gen Virol 74(Pt 3):501\u2013507","journal-title":"J Gen Virol"},{"issue":"8","key":"7027_CR36","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","volume":"88","author":"L Rees","year":"2009","unstructured":"Rees L, Tizard EJ, Morgan AJ, Cubitt WD, Finerty S, Oyewole-Eletu TA, Owen K, Royed C, Stevens SJ, Shroff RC, Tanday MK, Wilson AD, Middeldorp JM, Amlot PL, Steven NM (2009) A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 88(8):1025\u20131029","journal-title":"Transplantation"},{"key":"7027_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semcancer.2014.04.004","volume":"26","author":"AB Rickinson","year":"2014","unstructured":"Rickinson AB (2014) Co-infections, inflammation and oncogenesis: future directions for EBV research. Semin Cancer Biol 26:99\u2013115","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"7027_CR38","doi-asserted-by":"publisher","first-page":"e1002308","DOI":"10.1371\/journal.ppat.1002308","volume":"7","author":"J Sashihara","year":"2011","unstructured":"Sashihara J, Hoshino Y, Bowman JJ, Krogmann T, Burbelo PD, Coffield VM, Kamrud K, Cohen JI (2011) Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge. PLoS Pathog 7(10):e1002308","journal-title":"PLoS Pathog"},{"key":"7027_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coviro.2013.12.001","volume":"4","author":"C Shannon-Lowe","year":"2014","unstructured":"Shannon-Lowe C, Rowe M (2014) Epstein Barr virus entry; kissing and conjugation. Curr Opin Virol 4:78\u201384","journal-title":"Curr Opin Virol"},{"issue":"10","key":"7027_CR40","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6026\/97320630008479","volume":"8","author":"LS Sitompul","year":"2012","unstructured":"Sitompul LS, Widodo N, Djati MS, Utomo DH (2012) Epitope mapping of gp350\/220 conserved domain of Epstein Barr virus to develop nasopharyngeal carcinoma (NPC) vaccine. Bioinformation 8(10):479\u2013482","journal-title":"Bioinformation"},{"issue":"12","key":"7027_CR41","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/523813","volume":"196","author":"EM Sokal","year":"2007","unstructured":"Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Leonard P, Moreels A, Haumont M, Bollen A, Smets F, Denis M (2007) Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 196(12):1749\u20131753","journal-title":"J Infect Dis"},{"issue":"2","key":"7027_CR42","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0264-410X(98)00190-X","volume":"17","author":"JP Stewart","year":"1999","unstructured":"Stewart JP, Micali N, Usherwood EJ, Bonina L, Nash AA (1999) Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: a model system for gamma-herpesvirus vaccination. Vaccine 17(2):152\u2013157","journal-title":"Vaccine"},{"issue":"7","key":"7027_CR43","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1007\/s12010-014-0771-z","volume":"172","author":"M Subathra","year":"2014","unstructured":"Subathra M, Santhakumar P, Satyam Naidu S, Lakshmi Narasu M, Senthilkumar TM, Lal SK (2014) Expression of avian influenza virus (H5N1) hemagglutinin and matrix protein 1 in Pichia pastoris and evaluation of their immunogenicity in mice. Appl Biochem Biotechnol 172(7):3635\u20133645","journal-title":"Appl Biochem Biotechnol"},{"issue":"11","key":"7027_CR44","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/nsmb1161","volume":"13","author":"G Szakonyi","year":"2006","unstructured":"Szakonyi G, Klein MG, Hannan JP, Young KA, Ma RZ, Asokan R, Holers VM, Chen XS (2006) Structure of the Epstein-Barr virus major envelope glycoprotein. Nat Struct Mol Biol 13(11):996\u20131001","journal-title":"Nat Struct Mol Biol"},{"issue":"19","key":"7027_CR45","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","volume":"20","author":"GS Taylor","year":"2014","unstructured":"Taylor GS, Jia H, Harrington K, Lee LW, Turner J, Ladell K, Price DA, Tanday M, Matthews J, Roberts C, Edwards C, McGuigan L, Hartley A, Wilson S, Hui EP, Chan AT, Rickinson AB, Steven NM (2014) A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res 20(19):5009\u20135022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"7027_CR46","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s00253-006-0765-z","volume":"74","author":"D Teng","year":"2007","unstructured":"Teng D, Fan Y, Yang YL, Tian ZG, Luo J, Wang JH (2007) Codon optimization of Bacillus licheniformis \u03b2-1,3-1,4-glucanase gene and its expression in Pichia pastoris. Appl Microbiol Biotechnol 74(5):1074\u20131083","journal-title":"Appl Microbiol Biotechnol"},{"key":"7027_CR47","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1038\/emm.2014.102","volume":"47","author":"E Tse","year":"2015","unstructured":"Tse E, Kwong YL (2015) Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Exp Mol Med 47:e136","journal-title":"Exp Mol Med"},{"issue":"14","key":"7027_CR48","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.1007\/s00253-013-4967-x","volume":"97","author":"M Wang","year":"2013","unstructured":"Wang M, Jiang S, Liu X, Wang Y (2013) Expression, purification, and immunogenic characterization of Epstein-Barr virus recombinant EBNA1 protein in Pichia pastoris. Appl Microbiol Biotechnol 97(14):6251\u20136262","journal-title":"Appl Microbiol Biotechnol"},{"key":"7027_CR49","first-page":"248680","volume":"2015","author":"JR Wang","year":"2015","unstructured":"Wang JR, Li YY, Liu DN, Liu JS, Li P, Chen LZ, Xu SD (2015) Codon optimization significantly improves the expression level of \u03b1-amylase gene from Bacillus licheniformis in Pichia pastoris. Biomed Res Int 2015:248680","journal-title":"Biomed Res Int"},{"issue":"6","key":"7027_CR50","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1128\/jvi.61.6.1796-1807.1987","volume":"61","author":"Y Whang","year":"1987","unstructured":"Whang Y, Silberklang M, Morgan A, Munshi S, Lenny AB, Ellis RW, Kieff E (1987) Expression of the Epstein-Barr virus gp350\/220 gene in rodent and primate cells. J Virol 61(6):1796\u20131807","journal-title":"J Virol"},{"issue":"22","key":"7027_CR51","doi-asserted-by":"publisher","first-page":"11217","DOI":"10.1128\/JVI.01673-08","volume":"82","author":"KA Young","year":"2008","unstructured":"Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP (2008) Molecular basis of the interaction between complement receptor type 2 (CR2\/CD21) and Epstein-Barr virus glycoprotein gp350. J Virol 82(22):11217\u201311227","journal-title":"J Virol"},{"key":"7027_CR52","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1038\/srep03043","volume":"3","author":"P Yu","year":"2013","unstructured":"Yu P, Yan Y, Gu Q, Wang X (2013) Codon optimisation improves the expression of Trichoderma viride sp. endochitinase in Pichia pastoris. Sci Rep 3:3043","journal-title":"Sci Rep"}],"container-title":["Applied Microbiology and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-015-7027-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00253-015-7027-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-015-7027-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-015-7027-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T15:02:47Z","timestamp":1718118167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00253-015-7027-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["7027"],"URL":"https:\/\/doi.org\/10.1007\/s00253-015-7027-x","relation":{},"ISSN":["0175-7598","1432-0614"],"issn-type":[{"value":"0175-7598","type":"print"},{"value":"1432-0614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,3]]},"assertion":[{"value":"25 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was funded by the Promotive Research Fund for Excellent Young and Middle-Aged Scientists of Shandong Province (No. BS2014YY042) and the Natural Science Foundation of Shandong Province, China (No. ZR2015HQ012).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}